Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
T/O is easiest valuation - Basically a company is saying I will buy all the shares at X price). Shareholders consider offer. Share price will rise on the basis of offer if not suspended Once agreed by majority of shareholders (I don't know the percentage required) - money magically appears in your bank :-)
Anything else is a 'it depends' but price will rise significantly, e.g. if JV offers 1B +20% for North America then this adds 1B to the bank (3*current share price in cash), you also have cash flows for North America, and the ROW is still open for further deals....
Its global, short and long term. Any authorisation will generates sales and increase price.
This is literally gold - its only a matter of time. Of course, unless Global pharma cures viruses and COPD, comes up with a better treatment or Trial Results were a lie. Fortunately Synairgen hold (or applied for) patents for the formulation and delivery method of Interferon so this gives them an advantage.
Synairgen can be pushed into further trials and hoops to jump through but will essentially make it at some point because it works and ultimately it will get approved (MAP Process is already opening doors for use).
Did I miss anything?
Rasher - Filtered for being an obtuse twat with that drivel.
Can't even be arsed to argue why you're so wrong. Go watch Trump or something.
****ed off - missed a top-up at 1.60 (needed fund to sell) then 1.70 waiting for 1.60 then 1.70 this morning because it never happened. :-(
This was an increase on a over balanced portfolio - so still good. But still nearly 3000 shares extra would have been nice today.
Think this has already been posted, HL have confirm a default of AIM/CREST with no action required.
I'd be surprised if any (UK) broker decided to not to go this route for UK customers, I could be wrong.
Thanks Ghia.
That's interesting.
Oops... How clinigen works in Practice?
What volumes can be placed/distributed via Cliniport?
Are we looking at 100's/1000's/10,000s/100,000s of treatments that can be ordered/delivered via this method (i.e. is it scalable?)
Does anyone here know how Clinigen
"Only available to EU countries.....really...and you think the private hospitals or the larger ones will not just order this through the back door or get a delivery from an EU country? When desperation hits there is always a way!"
I suspect that this is very tightly controlled as (I understand) its on a patient by patient request - not sure this can happen unless a country designates widespread use. Also huge risk across the entire chain if something goes wrong with an open and shut lawsuit not to mention the lost of licences. I doubt any signature from a patient would remove liability.
The doctor has to explicitly request it for the patient. What scenario do you envisage a doctor in a UK private medical facility is going to request others to falsify information to obtain the drug? Drug just falls off an inventory....
Its a rhetorical question.
vfr800fix - So a French doctor posted on twitter that in 2 weeks time SNG will be authorised under ATU on 15th (and this is confirmed)
LOL - Happy ****ing days. Clinigen will probably be shipping by Air on the 15th/16th - by end October every French doctor in a hospital will be asking to use it - assuming results are nearly as good as the trials. Personally, Clinigen may even ship supplies in advance of the 15th for immediate delivery.
This is where we are at in the world. IMHO.
10k+ Infections per day in France currently, reports of ICUs full in hospitals in south, 1 in 20 i.e. 5% is the immediate target.
Potentially 500+ patients per day in serious circumstances. Do the maths.
Burford was my first serious buy last year.
Bought after MW attack with a view it was oversold and I could make a quick profit because MW attack was mostly rubbish (targeted attack). Caught a falling knife. Went back up, bought some more, was up 25% and forgot to sell (believed it would go higher/re-bounce when it fell). It didn't.
Bought more when it fell and ended up sitting on a 30% 'Loss' - averaged down some more. Became a mid to long term prospect.
Today that lost disappeared for the 1st time in a year - hopefully results + NYSE dual listing will create profit. Phew!
Probably hold for compound returns on growth, going for 150%+ profit in next few years (better than 1% in savings account). Rest are in funds except SNG - got hit by Woodford - which would have probably been looking pretty good by now.
You run a country and you have a massive problem with your citizens getting very ill and dying.
Your medical professionals can now access a safe but yet unlicensed medication to treat the patients which prevents their death. Surely you give the medical professionals the nod to request and use it? What's the alternative?
We live in an information age - surely with 100+ countries and several million infected word is going to get out fast if not already. I think most of us know what we are asking for if we end up in hospital with Covid - I'm not waiting for the ventilator. Perhaps we really need to key the word out as much as we can.
As of yesterday there is a method to obtain that treatment.... I would really have liked to have seen the UK GOV stepping up here. Seems negligent that they haven't as far as I can see - which is par for this government. They could literally tell there friends to load up and make a killing here!
If I had a job - I'd be adding here, but unfortunately I need to preserve cash for the immediate future.
I wouldn't listen to me though, I don't run a country and I'm so overexposed.
If I was in before Manic Monday, I wouldn't be giving a **** right now.
Okay, so I have a problem differentiating the possible channels and potential volumes (demand/sales).
RM has stated (and I paraphrase as I understand) they had some existing stock and would be producing 100,000 (s) doses per month in 2021.
We have the Home Trial which requires stock (I assume this will use existing stock so ignore.)
We have the MAP which requires stock.
And we aim for emergency/general approvals.
My questions which I can't get entirely clear (probably because I'm a simple man):
1.) What volume can we expect through MAP? Is this per patient or per hospital/trust? I assume supplies would need to be available in 'bulk' locally. Seems very inefficient not to have stock readily available for patients when you have 1000s globally per day potentially that would benefit.
2.) Is the the 100K doses per month to go through MAP or is this existing stock for MAP?
3.) 100K is a ramp up figure, I assume we don't go from 0 to 100K per month, so there was a mention of smaller batches, (remembering work started earlier in the year) so do with have additional batches for the MAP.
Additionally, what timeframes can we expect for approvals to sell via MAP (assuming that approvals will come). I think I saw earlier 4 weeks for UK.
I'm also trying to understand where the parallel streams lead. If sufficient volume can be pulled through MAP sooner rather than later this will help avoid cash flow crunches for ramping up assuming costs are higher in 2021.
Finally, does EUAs then create a distribution channel or is MAP/Clinigen used for distribution? (I assumed yesterday this would be Clinigen/Cliniport. Thanks J
Perhaps 'short-circuit' is the wrong phrase - yes 'authorised' at speed for use with patients (and chargeable). Not a further trial not a full formal authorisation/license.
Its compassionate use when you are hospitalised, can't breathe and the next stage is ventilation, permanent damage and potential death. It clearly won't be the last resort because that's currently Dex.
If we agree (from your own words) 'it will ONLY be available to patients that are about to die' that is still market access and currently there is a lot of them and its growing.....
Scinv - Thanks for your response. Its good to have different / varied views and thoughts. Questions are good.
My post, is really a question to everyone not a statement of truth/knowledge.
I think your first point does illustrate how this Market Access approach helps to 'short circuit' potential requirements for official authorisations in the short term and generates more data for these in the longer term. BTW - I'm not trying to persuade you on this, its just a thought.
I don't really have any solids re: manufacturing. They (SNG) would have had to manufacture for the trials so my initial assumption (which could be wrong) would be that they would discuss with the original manufacturers on scaling, this is is (obviously) outsourced and would be sub-contracted directly/indirectly. Providing there's funding this will be completed.
(It looks like 100K per month in 2021 which is more specific than the previously vague millions of doses.)
OMG - Note to self: proof read posts (properly). I can read and write, I promise :-)
Disclaimer: Not ramping/de-ramping . I am balls deep in and behind somewhat! Either way Long term I think we're good.
Is this quite a clever move overall?
1.) MAP - is this the quickest route to make SNG available (for SALE) whilst completing the necessary hoops (of which there can be further demands for approvals. As I understand it now - any government (or state) can now independently allow this to be used with the risk entirely on the patient. Basically its available to the market and avoids some hoops whilst approvals continue to be made.
2.) Its targeted to the most in need - yes ideally we'd all like it to available to everyone (including early on) but the capacity isn't there - saves more lives than if regularly available/widely used.
3.) Tie-up is logistics - this is key for sales.
4.) This derives income, provides further data (wide spread use in hospital patients will results in all sorts of data)
5.) I suspect more news to follow, maybe government announcements with funding to allow right to try.
6.) If Covid ends 2021 moves neatly into COPD 2021. (I think COVID runs into 2021 winter - maybe not as 'bad').
I suspect that SNG would have been advised that this would be the most appropriate/effective route to market for there situation and for future approvals?
7.) My main concern is cash flow - 10m isn't gonna last long if payment terms are 30-90 days. So expect that government funds to be in the mix somewhere without JV or takeover (which are still on the table as if going to shareholders/market).
Thanks Matml74
Bought 1071 Shares early doors (sub 8.30am) on HL - overpaid at 175 (yes I could have a better price).
Have been watching trades and it hasn't shown!
Another HL (later) trade I made Buy@171 has shown.
Can anyone see all trades today to confirm it hasn't been posted? Would the notification be held back because its 'over' the spread that is being driven this morning. Hate to be all conspiracy, just seems odd. Noted a 177 buy from 8.01am has only been posted. Seems odd or just administrative paranoia?
“Shareholders will need to decide if they want to continue to hold their share under Crest or change to the US analogy “
What does this mean in practice?
I assume that the price will be consistent across exchanges?
If you opt for the US analogy, isn't this effectively trading as an American share therefore additional paperwork/declarations to complete?
Never done this so no idea what it entails.
MrBig - Thanks.
'In poker terminology you should never play the stakes that your bankroll can't support.'
This is not entirely true. It is widely known (from poker interviews/books) that many successful professionals took shots at the big league outside their bankroll, and many went broke (sometimes more than once) before they hit the big time.
Many (successful) players who made it in the Poker world advocate (or advocated) taking shots to hit the big league - some even wished that they'd done it earlier.
Also, many players made money in the boom years, did so fortunately by being in the right place and the right time having the 'perfect' storm of the poker boom. Ironically many of those weren't very good and went broke later - probably because they were degenerate gamblers (and poker standards improved massively in the following years). So Swings and Roundabouts.
Back to SNG.